Cross-protective potential of anti-nucleoprotein human monoclonal antibodies against lethal influenza A virus infection
- PMID: 27260213
- DOI: 10.1099/jgv.0.000518
Cross-protective potential of anti-nucleoprotein human monoclonal antibodies against lethal influenza A virus infection
Abstract
The nucleoprotein (NP) possesses regions that are highly conserved among influenza A viruses, and has therefore been one of the target viral proteins for development of a universal influenza vaccine. It has been expected that human or humanized antibodies will be made available for the prophylaxis, pre-emptive and acute treatment of viral infection. However, it is still unclear whether anti-NP human antibody can confer protection against influenza virus infection. In this study, we generated transgenic mice expressing anti-NP human mAbs derived from lymphocytes of a patient infected with H5N1 highly pathogenic avian influenza (HPAI) virus, and experimental infections were conducted to examine antiviral effects of the anti-NP antibodies against H5N1 HPAI viral infections with a high fatality rate in mammals. Transgenic mouse lines expressing the anti-NP human mAbs at more than 1 mg ml-1 showed marked resistance to H5N1 virus infections. In addition, resistance to infection with an H1N1 subtype that shows strong pathogenicity to mice was also confirmed. Although the anti-NP mAbs expressed in the transgenic mice did not neutralize the virus, the mAbs could bind to NP located on the surface of infected cells. These results suggested a possibility that the non-neutralizing anti-NP human mAbs could induce indirect antiviral effects, such as antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity. Taken together, these results demonstrated that anti-NP human mAbs play an important role in heterosubtypic protection against lethal influenza virus infections in vivo.
Similar articles
-
Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses.J Virol. 2013 May;87(10):5985-93. doi: 10.1128/JVI.00120-13. Epub 2013 Mar 20. J Virol. 2013. PMID: 23514880 Free PMC article.
-
A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.Virol J. 2010 Aug 21;7:197. doi: 10.1186/1743-422X-7-197. Virol J. 2010. PMID: 20727202 Free PMC article.
-
Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.Microb Cell Fact. 2015 Aug 5;14:111. doi: 10.1186/s12934-015-0287-4. Microb Cell Fact. 2015. PMID: 26242406 Free PMC article.
-
Development of universal influenza vaccines based on influenza virus M and NP genes.Infection. 2014 Apr;42(2):251-62. doi: 10.1007/s15010-013-0546-4. Epub 2013 Nov 1. Infection. 2014. PMID: 24178189 Review.
-
Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery.Int Rev Immunol. 2009;28(1):69-92. doi: 10.1080/08830180802593540. Int Rev Immunol. 2009. PMID: 19241254 Review.
Cited by
-
Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed Toward the Nucleoprotein.J Infect Dis. 2017 Mar 1;215(5):818-823. doi: 10.1093/infdis/jiw629. J Infect Dis. 2017. PMID: 28011910 Free PMC article.
-
Nucleoprotein as a Promising Antigen for Broadly Protective Influenza Vaccines.Vaccines (Basel). 2023 Nov 23;11(12):1747. doi: 10.3390/vaccines11121747. Vaccines (Basel). 2023. PMID: 38140152 Free PMC article. Review.
-
Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.Front Immunol. 2019 Mar 29;10:646. doi: 10.3389/fimmu.2019.00646. eCollection 2019. Front Immunol. 2019. PMID: 30984200 Free PMC article.
-
Antiviral effects against influenza A virus infection by a short hairpin RNA targeting the non-coding terminal region of the viral nucleoprotein gene.J Vet Med Sci. 2019 Mar 14;81(3):383-388. doi: 10.1292/jvms.18-0436. Epub 2019 Jan 22. J Vet Med Sci. 2019. PMID: 30674743 Free PMC article.
-
Influenza and Antibody-Dependent Cellular Cytotoxicity.Front Immunol. 2019 Jun 25;10:1457. doi: 10.3389/fimmu.2019.01457. eCollection 2019. Front Immunol. 2019. PMID: 31316510 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous